• Swiss Researchers Pioneer Multiomics Diagnostics for Cancer Treatment Selection

    Jul 18 | Diagnostics World | Swiss researchers have achieved a significant breakthrough in cancer diagnostics, demonstrating that advanced multiomics testing can successfully predict the most effective treatments for melanoma patients within four weeks—a timeline fast enough for real-world clinical use. More
  • Alzheimer's Biomarker Found at Surprisingly High Levels in Newborns Challenges Diagnostic Assumptions

    Jul 17 | Diagnostics World | A study has revealed that phosphorylated tau (p-tau217), a key biomarker for Alzheimer's disease diagnosis, appears at even higher levels in healthy newborns than in adults with Alzheimer's disease—a finding that could reshape how clinicians interpret this widely-used diagnostic tool. More
  • Startups Taking Multi-Cancer Early Detection Testing to the Next Level

    Jul 10 | Diagnostics World | A growing number of promising young companies are developing tests that are particularly good at picking up early cancer, initially for a single type of cancer but with the potential to eventually be extended to multiple cancer types. A handful of these startups will be spotlighted at the upcoming Next Generation Dx Summit . More
  • Fragmentation Approach to Finding Remnants of Cancer in the Blood

    Jul 09 | Diagnostics World | Molecular testing for minimal residual disease (MRD) is increasingly being used to detect cancer recurrence, and to that end many companies are actively developing assays. The tumor-informed approach based on the genetic mutations of patients has been particularly popular and often employs cell-free DNA (cfDNA) and more specifically circulating tumor DNA (ctDNA) analysis. More
  • Blood Test Detects Cancer with 95% Accuracy Using Microbiome RNA

    Jul 08 | Diagnostics World | Researchers at the University of Chicago have published a new approach to cancer detection offering early unprecedented accuracy in identifying both early and late-stage cancers through a simple blood plasma test. The results were published today in a Brief Communication in Nature Biotechnology More
  • Digital Pathology’s Flywheel Effect: Growing Momentum, Growing Opportunity

    Jul 03 | Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns. More
  • Digital Microfluidics Expanding the Value of Syndromic Testing

    Jul 01 | Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns. More
  • Galatea Bio, Fabric Genomics Combine Pathogenic Variant Analysis with Polygenic Risk Score

    Jun 26 | Diagnostics World | Galatea Bio and Fabric Genomics announced a strategic collaboration this week to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. More
  • Follow the Money: Neuroplastogens Novel Therapies, Genetic Medicines, More

    Jun 25 | Diagnostics World | Elkedonia SAS plans to develop the drug-like small molecule inhibitors of Elk1, a novel intracellular target that plays a pivotal role in reward brain circuits and neuroplasticity; SpliceBio will advance the clinical development of their lead gene therapy candidate, SB-007, for Stargardt disease; and more. More
  • Veeva, Sarah Cannon Research Institute Collaboration, City of Hope Receives Grant, More

    Jun 24 | Diagnostics World | Veeva and Sarah Cannon Research Institute has entered a strategic collaboration; City of Hope was awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the US Department of Health and Human Services; and more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more